Factor Xa Inhibitors

"Factor Xa Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Endogenous factors and drugs that inhibit or block the activity of FACTOR XA.

Descriptor ID	D065427
MeSH Number(s)	D27.505.519.389.745.800.449.500 D27.505.954.502.119.500.500
Concept/Terms	Factor Xa Inhibitors Factor Xa Inhibitors Inhibitors, Factor Xa Direct Factor Xa Inhibitors

Below are MeSH descriptors whose meaning is more general than "Factor Xa Inhibitors".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Molecular Mechanisms of Pharmacological Action [D27.505.519]
Enzyme Inhibitors [D27.505.519.389]
Protease Inhibitors [D27.505.519.389.745]
Serine Proteinase Inhibitors [D27.505.519.389.745.800]
Antithrombins [D27.505.519.389.745.800.449]
Factor Xa Inhibitors [D27.505.519.389.745.800.449.500]
Therapeutic Uses [D27.505.954]
Hematologic Agents [D27.505.954.502]
Anticoagulants [D27.505.954.502.119]
Antithrombins [D27.505.954.502.119.500]
Factor Xa Inhibitors [D27.505.954.502.119.500.500]

Below are MeSH descriptors whose meaning is related to "Factor Xa Inhibitors".

Below are MeSH descriptors whose meaning is more specific than "Factor Xa Inhibitors".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Factor Xa Inhibitors" by people in this website by year, and whether "Factor Xa Inhibitors" was a major or minor topic of these publications.

Bar chart showing 20 publications over 10 distinct years, with a maximum of 5 publications in 2020

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2007	1	0	1
2014	0	1	1
2017	1	0	1
2018	1	0	1
2019	3	1	4
2020	3	2	5
2021	0	1	1
2023	0	4	4
2024	0	1	1
2025	1	0	1

Below are the most recent publications written about "Factor Xa Inhibitors" by people in Profiles.

Yaghi S, Shu L, Mistry EA, Adeoye O, Schwamm L, Messe S, Elkind MSV, Ghannam M, de Havenon A, Furie K, Xian Y, Streib C, Wangqin R, Henninger N, Saver JL, Smith EE. Intravenous Thrombolysis in Patients on Direct Oral Anticoagulants: Analysis of the Get With The Guidelines Stroke Registry. J Am Heart Assoc. 2026 Jan 06; 15(1):e044321.

View in: PubMed
Xiao H, Meng X, Li Z, Fang S, Wang Y, Li J, Tang J, Ma L. Combined drug anti-deep vein thrombosis therapy based on platelet membrane biomimetic targeting nanotechnology. Biomaterials. 2024 Dec; 311:122670.

View in: PubMed
Hwang YJ, Chang HY, Metkus T, Andersen KM, Singh S, Alexander GC, Mehta HB. Risk of Major Bleeding Associated with Concomitant Direct-Acting Oral Anticoagulant and Clopidogrel Use: A Retrospective Cohort Study. Drug Saf. 2024 Mar; 47(3):251-260.

View in: PubMed
Kapoor A. The Leave Safe with DOACs Randomized Controlled Trial. J Gen Intern Med. 2024 04; 39(5):880.

View in: PubMed
Faisaluddin M, Alwifati N, Naeem N, Balasubramanian S, Narasimhan B, Iqbal U, Dani SS. Safety and Efficacy of Direct Oral Anticoagulants Versus Warfarin for Atrial Fibrillation in End-Stage Renal Disease on Hemodialysis: A Meta-Analysis of Randomized Control Trials. Am J Cardiol. 2023 Nov 01; 206:309-311.

View in: PubMed
Huang J, Mazer CD, Boisen ML, Tibi P, Baker RA, Chu D, Moffatt-Bruce S, Shore-Lesserson L. Safety of Andexanet Alfa Use in Cardiac Surgery. J Cardiothorac Vasc Anesth. 2023 07; 37(7):1332-1334.

View in: PubMed
Weiss L, Keaney J, Szklanna PB, Prendiville T, Uhrig W, Wynne K, Kelliher S, Ewins K, Comer SP, Egan K, O'Rourke E, Moran E, Petrov G, Patel A, Lennon ?, Blanco A, Kevane B, Murphy S, N? ?inle F, Maguire PB. Nonvalvular atrial fibrillation patients anticoagulated with rivaroxaban compared with warfarin exhibit reduced circulating extracellular vesicles with attenuated pro-inflammatory protein signatures. J Thromb Haemost. 2021 10; 19(10):2583-2595.

View in: PubMed
Bigos R, Solomon E, Dorfman JD, Ha M. A Weight- and Anti-Xa-Guided Enoxaparin Dosing Protocol for venous thromboembolism Prophylaxis in intensive care unit Trauma Patients. J Surg Res. 2021 09; 265:122-130.

View in: PubMed
Lawlor M, Gupta A, Ranard LS, Madhavan MV, Li J, Eisenberger A, Parikh SA, Sethi SS, Masoumi A. Discordance in activated partial thromboplastin time and anti-factor Xa levels in COVID-19 patients on heparin therapy. Thromb Res. 2021 02; 198:79-82.

View in: PubMed
Maatman TK, McGuire SP, Lewellen KA, McGreevy KA, Ceppa EP, House MG, Nakeeb A, Nguyen TK, Schmidt CM, Zyromski NJ. Prospective Analysis of the Mechanisms Underlying Ineffective Deep Vein Thrombosis Prophylaxis in Necrotizing Pancreatitis. J Am Coll Surg. 2021 01; 232(1):91-100.

View in: PubMed

People

Explore

Similar Concepts

Top Journals